When older adolescents miss part of their MenABCWY vaccination series, they remain vulnerable1,2

Teens are at increased risk of infection from all 5 leading meningococcal serogroups3,4

Risk posed by all
5

leadingserogroups

(A, B, C, W, and Y) rises between the ages of 15 and 22.4*

older adolescents walking across the schoolyard together

Actor portrayal.

>

0

%

of meningococcal disease cases in the US are caused by serogroups A, B, C, W, and Y.3*

*Serogroup B was responsible for 39.5% of cases, serogroup C for 23.0% of cases, serogroup Y for 25.4% of cases, and serogroup W for 0.4% of cases in the United States during 1998-2012. Serogroup A was responsible for 0.5% of cases in the Americas. Totals based on a meta-analysis of 102 global studies. Demographics varied across studies, and included infants, adolescents, and adults.3
older adolescents huddled together during a sports game

Actor portrayal.

*Serogroup B was responsible for 39.5% of cases, serogroup C for 23.0% of cases, serogroup Y for 25.4% of cases, and serogroup W for 0.4% of cases in the United States during 1998-2012. Serogroup A was responsible for 0.5% of cases in the Americas. Totals based on a meta-analysis of 102 global studies. Demographics varied across studies, and included infants, adolescents, and adults.3
*Serogroup B was responsible for 39.5% of cases, serogroup C for 23.0% of cases, serogroup Y for 25.4% of cases, and serogroup W for 0.4% of cases in the United States during 1998-2012. Serogroup A was responsible for 0.5% of cases in the Americas. Totals based on a meta-analysis of 102 global studies. Demographics varied across studies, and included infants, adolescents, and adults.3

CDC’s ACIP recommends MenABCWY coverage for all eligible healthy teens2†‡

The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination with a MenACWY vaccine for all adolescents, with the first dose at age 11 or 12 years and a booster dose at age 16. Adolescents who receive the first dose at age 13 to 15 years should receive a booster dose at age 16 to 18 years, with a minimum interval of 8 weeks between doses. Adolescents who receive their first dose of MenACWY vaccine at or after age 16 years do not need a booster dose.

ACIP also recommends adolescents age 16 to 23 years (preferred age 16 to 18 years) receive 2 doses of a MenB vaccine for short-term protection against most strains of serogroup B meningococcal disease based on shared clinical decision-making.

†For further guidance on individuals in older age groups or at increased risk, please click the button.

Most healthcare professionals, like you, recommend vaccinating eligible teens against all 5 leading meningococcal serogroups5‡
most healthcare professionals believe vaccinating eligible teens against the 5 leading meningococcal serogroups is vitalmost healthcare professionals believe vaccinating eligible teens against the 5 leading meningococcal serogroups is vital
In a recent survey of HCPs (n=500):
95.6%
of HCPs highly recommend all of their teen patients get all recommended meningococcal vaccines (ACWY and B) and required doses to help protect against all 5 leading serogroups.5
75.2%
of HCPs agree that most parents incorrectly believe their teen is fully protected against all 5 leading serogroups.5
98.6%
of HCPs agree a combined MenABCWY vaccine that covers all 5 leading serogroups can help close gaps in protection and increase vaccination rates in teens.5
syringe icon for vaccination against the 5 most common meningococcal serogroups
Closing gaps in meningococcal vaccination starts with you—vaccinate your eligible older adolescent patients against all 5 leading meningococcal serogroups.3,6‡
icon for gaps in vaccine coverage against the 5 leading serogroups leaves many teens at risk for meningococcal disease

Gaps in Coverage

Gaps in coverage against all 5 leading serogroups leave most older adolescents at risk3,6

See More

icon for learning about a meningococcal vaccine

A New Option

Learn about a new vaccine that could help you close gaps in coverage7

Discover

‡ACIP recommends routine administration of a MenACWY vaccine for all healthy persons aged 11 to 18 years, with a single dose at age 11 or 12, followed by a booster dose at age 16. ACIP also recommends a 2-dose MenB vaccine series administered 1 to 6 months apart for healthy persons aged 16 to 23 years on the basis of shared clinical decision-making, with a preferred age range of 16 to 18. For further guidance on individuals in older age groups or at increased risk, see ACIP Meningococcal Vaccine Recommendations.2

CDC=Centers for Disease Control and Prevention; HCP=healthcare professional.

References

  1. Vaccines and preventable diseases: meningococcal vaccination. Centers for Disease Control and Prevention. Last reviewed October 12, 2021. Accessed August 2, 2023. https://www.cdc.gov/vaccines/vpd/mening/index.html

  2. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1-41.

  3. Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134:103571.

  4. Meningococcal disease: surveillance data tables. Centers for Disease Control and Prevention. Last reviewed July 10, 2023. Accessed September 11, 2023. https://www.cdc.gov/meningococcal/surveillance/surveillance-data.html

  5. Data on file. Pfizer; 2023.

  6. ‌Pingali C, Yankey D, Elam-Evans LD, et al. Vaccination coverage among adolescents aged 13–17 years—National Immunization Survey–Teen, United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(34):912-919.

  7. Kroger A, Bahta L, Long S, Sanchez P. Vaccine recommendations and guidelines of the ACIP: general best practice guidelines for immunization. Centers for Disease Control and Prevention. Accessed August 31, 2023. https://www.cdc.gov/vaccines/hcp/acip-recs/generalrecs/downloads/general-recs.pdf